Please ensure Javascript is enabled for purposes of website accessibility

Why BioNTech Stock Was Sliding Today

By Eric Volkman - Jun 16, 2021 at 4:38PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An analyst unceremoniously chops his recommendation on the stock.

What happened

BioNTech (BNTX 1.33%) shares were having an atypically bad day on Wednesday, and by the close of trading were down by nearly 7%. A downshift in one analyst's recommendation seems to be the latest headwind buffeting the company's stock.

So what

Analyst Simon Baker at Redburn Securities changed his recommendation on the stock to sell from neutral, tagging it with a $146 per share target price. That's nearly 30% below its current level.

Child receiving a vaccine shot while being comforted by an adult.

Image source: Getty Images.

His reasoning, detailed in a research note published Wednesday, is that the sturdy gains the stock has enjoyed since the end of March are not justified by the biotech's most recent guidance or by the considerable revenue the company still stands to take in from the coronavirus vaccine it developed in partnership with Pfizer (PFE -0.72%).

Wednesday's investor bearishness was also related to Monday's news from Novavax. The vaccine specialist announced stunningly positive phase 3 clinical trial results for its NVX-CoV2373 COVID-19 vaccine candidate. They showed more than 90% efficacy overall, and 100% against moderate and severe instances of the disease.

Now what

So basically, it's been a tough week for BioNTech, which perhaps seems as if it's becoming yesterday's coronavirus vaccine news. Yet the pandemic is far from over, and the BioNTech/Pfizer jab is one of the best in class. Meanwhile, the messenger RNA (mRNA) technology used in that shot is only in its beginning stages, promising a bright future for BioNTech -- which has a wide pipeline stuffed with mRNA-based products.  

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioNTech SE Stock Quote
BioNTech SE
BNTX
$162.48 (1.33%) $2.13
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.75 (-0.72%) $0.36
Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$42.30 (2.00%) $0.83

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.